People wonder whether anti-aging breakthroughs will actually arrive in time for them to benefit.
In this video, we look at what’s already in human trials, what’s coming next, and the realistic timelines for genuine aging-targeted therapies.
We cover:
• The current pipeline of drugs that target aging biology (rapamycin analogs, senolytics, NAD⁺ restoration, GLP-1s, SGLT2 inhibitors, metformin)
• What nutrition trials revealed about slowing biological aging in healthy adults
• Why epigenetic clocks are accelerating human geroscience research
• How long it takes for mouse longevity interventions to translate into real human therapies
• Why the 2030s are the likely decade for the first true “healthspan drugs”
• The odds of people under 50 living long enough to benefit from multiple therapy waves
• Why adding healthy years now drastically increases your chance of reaching future breakthroughs
The real question isn’t immortality, it’s whether treatments that add 5–15 extra healthy years will arrive within our lifetime.
For most adults today, the answer is very likely yes.
If you want longevity guidance and clear explanations of what actually moves the needle, subscribe. There’s much more coming.
